Researchers at EPFL reported a preclinical CAR‑T platform, named DROP‑CAR, that can be rapidly and reversibly deactivated using the approved cancer drug venetoclax. Published in Nature Chemical Biology, the team showed the approach disengages CAR‑T cell binding to targets without destroying the engineered cells, reducing on‑target, off‑tumor toxicity risk in mouse cancer models. The method leverages a clinically realistic small‑molecule 'remote control' to modulate cell‑cell interactions and could broaden CAR‑T applicability, particularly against solid tumors where safety constraints have limited development.